WO1999002560A1 - Hoqbq59 - Google Patents
Hoqbq59 Download PDFInfo
- Publication number
- WO1999002560A1 WO1999002560A1 PCT/US1998/014291 US9814291W WO9902560A1 WO 1999002560 A1 WO1999002560 A1 WO 1999002560A1 US 9814291 W US9814291 W US 9814291W WO 9902560 A1 WO9902560 A1 WO 9902560A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- hoqbq59
- seq
- nucleotide sequence
- polynucleotide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 202
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 196
- 229920001184 polypeptide Polymers 0.000 claims abstract description 193
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 84
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 84
- 239000002157 polynucleotide Substances 0.000 claims abstract description 83
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 31
- 230000000694 effects Effects 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000000556 agonist Substances 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 24
- 208000011580 syndromic disease Diseases 0.000 abstract description 22
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 18
- 238000003556 assay Methods 0.000 abstract description 15
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 230000006378 damage Effects 0.000 abstract description 12
- 230000002538 fungal effect Effects 0.000 abstract description 12
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 11
- 208000019901 Anxiety disease Diseases 0.000 abstract description 11
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 11
- 208000035143 Bacterial infection Diseases 0.000 abstract description 11
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 11
- 208000020925 Bipolar disease Diseases 0.000 abstract description 11
- 206010065687 Bone loss Diseases 0.000 abstract description 11
- 208000032841 Bulimia Diseases 0.000 abstract description 11
- 206010006550 Bulimia nervosa Diseases 0.000 abstract description 11
- 206010006895 Cachexia Diseases 0.000 abstract description 11
- 206010007556 Cardiac failure acute Diseases 0.000 abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 11
- 206010012218 Delirium Diseases 0.000 abstract description 11
- 206010012289 Dementia Diseases 0.000 abstract description 11
- 201000004624 Dermatitis Diseases 0.000 abstract description 11
- 208000012661 Dyskinesia Diseases 0.000 abstract description 11
- 206010017533 Fungal infection Diseases 0.000 abstract description 11
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 11
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 11
- 206010020772 Hypertension Diseases 0.000 abstract description 11
- 208000001953 Hypotension Diseases 0.000 abstract description 11
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract description 11
- 208000031888 Mycoses Diseases 0.000 abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 abstract description 11
- 208000025966 Neurological disease Diseases 0.000 abstract description 11
- 208000001132 Osteoporosis Diseases 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 11
- 208000018737 Parkinson disease Diseases 0.000 abstract description 11
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 11
- 208000010362 Protozoan Infections Diseases 0.000 abstract description 11
- 201000004681 Psoriasis Diseases 0.000 abstract description 11
- 208000028017 Psychotic disease Diseases 0.000 abstract description 11
- 206010040070 Septic Shock Diseases 0.000 abstract description 11
- 208000036623 Severe mental retardation Diseases 0.000 abstract description 11
- 208000024313 Testicular Neoplasms Diseases 0.000 abstract description 11
- 206010057644 Testis cancer Diseases 0.000 abstract description 11
- 208000025865 Ulcer Diseases 0.000 abstract description 11
- 206010046555 Urinary retention Diseases 0.000 abstract description 11
- 208000036142 Viral infection Diseases 0.000 abstract description 11
- 208000027418 Wounds and injury Diseases 0.000 abstract description 11
- 230000007815 allergy Effects 0.000 abstract description 11
- 208000022531 anorexia Diseases 0.000 abstract description 11
- 230000036506 anxiety Effects 0.000 abstract description 11
- 208000006673 asthma Diseases 0.000 abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 11
- 208000028683 bipolar I disease Diseases 0.000 abstract description 11
- 206010061428 decreased appetite Diseases 0.000 abstract description 11
- 210000002816 gill Anatomy 0.000 abstract description 11
- 230000036543 hypotension Effects 0.000 abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 abstract description 11
- 208000014674 injury Diseases 0.000 abstract description 11
- 208000010125 myocardial infarction Diseases 0.000 abstract description 11
- 201000008482 osteoarthritis Diseases 0.000 abstract description 11
- 208000023504 respiratory system disease Diseases 0.000 abstract description 11
- 208000037803 restenosis Diseases 0.000 abstract description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 11
- 201000000980 schizophrenia Diseases 0.000 abstract description 11
- 230000036303 septic shock Effects 0.000 abstract description 11
- 201000003120 testicular cancer Diseases 0.000 abstract description 11
- 231100000397 ulcer Toxicity 0.000 abstract description 11
- 230000009385 viral infection Effects 0.000 abstract description 11
- 208000031886 HIV Infections Diseases 0.000 abstract description 8
- 241000713340 Human immunodeficiency virus 2 Species 0.000 abstract description 8
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 3
- 208000023105 Huntington disease Diseases 0.000 abstract description 2
- 238000010188 recombinant method Methods 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 52
- 239000012634 fragment Substances 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 239000000203 mixture Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 21
- 239000002299 complementary DNA Substances 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 17
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 17
- 238000009472 formulation Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 238000012545 processing Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 7
- CGOMLCQJEMWMCE-STQMWFEESA-N Phe-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CGOMLCQJEMWMCE-STQMWFEESA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 238000007423 screening assay Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KAJAOGBVWCYGHZ-JTQLQIEISA-N Gly-Gly-Phe Chemical compound [NH3+]CC(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KAJAOGBVWCYGHZ-JTQLQIEISA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 2
- UGZUVYDKAYNCII-ULQDDVLXSA-N Arg-Phe-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O UGZUVYDKAYNCII-ULQDDVLXSA-N 0.000 description 2
- QGABLMITFKUQDF-DCAQKATOSA-N Asn-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGABLMITFKUQDF-DCAQKATOSA-N 0.000 description 2
- XJQRWGXKUSDEFI-ACZMJKKPSA-N Asp-Glu-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O XJQRWGXKUSDEFI-ACZMJKKPSA-N 0.000 description 2
- GGRSYTUJHAZTFN-IHRRRGAJSA-N Asp-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O GGRSYTUJHAZTFN-IHRRRGAJSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- REPPKAMYTOJTFC-DCAQKATOSA-N Leu-Arg-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O REPPKAMYTOJTFC-DCAQKATOSA-N 0.000 description 2
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 2
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 2
- OZVXDDFYCQOPFD-XQQFMLRXSA-N Lys-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N OZVXDDFYCQOPFD-XQQFMLRXSA-N 0.000 description 2
- KAHUBGWSIQNZQQ-KKUMJFAQSA-N Phe-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KAHUBGWSIQNZQQ-KKUMJFAQSA-N 0.000 description 2
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 2
- RFEXGCASCQGGHZ-STQMWFEESA-N Phe-Gly-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O RFEXGCASCQGGHZ-STQMWFEESA-N 0.000 description 2
- FRMKIPSIZSFTTE-HJOGWXRNSA-N Phe-Tyr-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FRMKIPSIZSFTTE-HJOGWXRNSA-N 0.000 description 2
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 description 2
- XIFAHCUNWWKUDE-DCAQKATOSA-N Val-Cys-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XIFAHCUNWWKUDE-DCAQKATOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CNKBMTKICGGSCQ-ACRUOGEOSA-N (2S)-2-[[(2S)-2-[[(2S)-2,6-diamino-1-oxohexyl]amino]-1-oxo-3-phenylpropyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CNKBMTKICGGSCQ-ACRUOGEOSA-N 0.000 description 1
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 description 1
- XJFPXLWGZWAWRQ-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O XJFPXLWGZWAWRQ-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QKSAZKCRVQYYGS-UWVGGRQHSA-N Arg-Gly-His Chemical compound N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O QKSAZKCRVQYYGS-UWVGGRQHSA-N 0.000 description 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 1
- FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- VBPGTULCFGKGTF-ACZMJKKPSA-N Cys-Glu-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VBPGTULCFGKGTF-ACZMJKKPSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000255582 Drosophilidae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 108010072062 GEKG peptide Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 1
- QNJNPKSWAHPYGI-JYJNAYRXSA-N Glu-Phe-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 QNJNPKSWAHPYGI-JYJNAYRXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 1
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 1
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical group C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- HBGKOLSGLYMWSW-DCAQKATOSA-N His-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CS)C(=O)O HBGKOLSGLYMWSW-DCAQKATOSA-N 0.000 description 1
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 1
- 101000917519 Homo sapiens rRNA 2'-O-methyltransferase fibrillarin Proteins 0.000 description 1
- 101000615747 Homo sapiens tRNA-splicing endonuclease subunit Sen2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- WRLPVDVHNWSSCL-MELADBBJSA-N Leu-His-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@@H]2C(=O)O)N WRLPVDVHNWSSCL-MELADBBJSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- FIZZULTXMVEIAA-IHRRRGAJSA-N Met-Ser-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FIZZULTXMVEIAA-IHRRRGAJSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- HXSUFWQYLPKEHF-IHRRRGAJSA-N Phe-Asn-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N HXSUFWQYLPKEHF-IHRRRGAJSA-N 0.000 description 1
- PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 1
- ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- WXWDPFVKQRVJBJ-CIUDSAMLSA-N Ser-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N WXWDPFVKQRVJBJ-CIUDSAMLSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 230000010516 arginylation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- -1 cationic lipid Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 102100029526 rRNA 2'-O-methyltransferase fibrillarin Human genes 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 102100021774 tRNA-splicing endonuclease subunit Sen2 Human genes 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the RNA processing family, hereinafter referred to as HOQBQ59. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides. BACKGROUND OF THE INVENTION
- RNA processing is a fundamental biological process for all eukaryotic cells. All types of pre-RNAs (pre-tRNA, pre-mRNA, and pre-rRNA) are processed post-transcriptionally.
- pre-tRNA processing is carried out by a complex whose catalytic subunit is encoded by SEN2; mRNA processing is carried out by a complex (the splicesome), which contains both proteins and RNAs; and rRNA is processed in the nucleolus by snRNPS (small nuclear ribonuclear proteins which consist of proteins and snoRNAs).
- snRNPS small nuclear ribonuclear proteins which consist of proteins and snoRNAs.
- a yeast protein involved in RNA processing, NOP1 can be complemented by its human homolog, fibrillarin.
- yeast proteins have been found to be similar to Noplp based on sequence homology. These proteins all contain WD-40 repeats which are also contained in beta-subunits of trimeric G- proteins. Deficiencies in pre-mRNA splicing can result in aberrant message expression and decreased levels of expression of processed mRNA. Many genetic diseases, such as Gauchers disease, Alzheimer's disease, and cancer have been mapped to mutations which result in incorrect splicing. The resulting mRNAs then code for proteins which are either nonfunctional or have an altered function. Mutations in genes which are required for efficient processing of pre-mRNA may similarly be expected to effect gene expression.
- RNA processing family has an established, proven history as therapeutic targets.
- inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (HBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypert
- the invention relates to HOQBQ59 polypeptides and recombinant materials and methods for their production.
- Another aspect of the invention relates to methods for using such HOQBQ59 polypeptides and polynucleotides.
- Such uses include the treatment of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (TBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers;
- the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with HOQBQ59 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate HOQBQ59 activity or levels.
- HOQBQ59 refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.
- HOQBQ59 activity or HOQBQ59 polypeptide activity or “biological activity of the HOQBQ59 or HOQBQ59 polypeptide” refers to the metabolic or physiologic function of said HOQBQ59 including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said HOQBQ59.
- HOQBQ59 gene refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO:l or allelic variants thereof and/or their complements.
- Antibodies as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
- Isolated means altered “by the hand of man” from the natural state. If an "isolated” composition or substance occurs in nature, it has been changed or removed from its original environment, or both.
- a polynucleotide or a polypeptide naturally present in a living animal is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.
- Polynucleotide generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
- Polynucleotides include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double- stranded or a mixture of single- and double-stranded regions.
- polynucleotide refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA.
- the term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons.
- Modified bases include, for example, tritylated bases and unusual bases such as inosine.
- polynucleotide embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells.
- Polynucleotide also embraces relatively short polynucleotides, often referred to as oligonucleotides.
- Polypeptide refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. , peptide isosteres.
- Polypeptide refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
- Polypeptides include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature.
- Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side- chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods.
- Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- Variant is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties.
- a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
- a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
- a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
- a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
- a variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
- Identity is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity” per se has an art-recognized meaning and can be calculated using published techniques. See, e.g. : (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING:
- identity is well known to skilled artisans (Carillo, H., and Lipton, D., SLAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAMJ Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs.
- Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J. , et al. , Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al. , J Molec Biol (1990) 215:403).
- a polynucleotide having a nucleotide sequence having at least, for example, 95 % "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1.
- a polynucleotide having a nucleotide sequence at least 95 % identical to a reference nucleotide sequence up to 5 % of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5 % of the total nucleotides in the reference sequence may be inserted into the reference sequence.
- These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2.
- the polypeptide sequence having an amino acid sequence at least 95 % identical to a reference amino acid sequence up to 5 % of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5 % of the total amino acid residues in the reference sequence may be inserted into the reference sequence.
- These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
- the present invention relates to HOQBQ59 polypeptides (or HOQBQ59 proteins) .
- the HOQBQ59 polypeptides include the polypeptide of SEQ ID NOS: 2 and 4; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95 % identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within
- HOQBQ59 polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95 % identity to SEQ ID NO:2. Furthermore, those with at least 97- 99% are highly preferred.
- HOQBQ59 polypeptide exhibit at least one biological activity of HOQBQ59.
- the HOQBQ59 polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro- sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.
- Fragments of the HOQBQ59 polypeptides are also included in the invention.
- a fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned HOQBQ59 polypeptides.
- fragments may be "free-standing, " or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region.
- Representative examples of polypeptide fragments of the invention include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of HOQBQ59 polypeptide.
- “about” includes the particularly recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.
- Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of HOQBQ59 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl teraiinus.
- fragments characterized by stractural or functional attributes such as fragments that comprise alpha-helix and alpha- helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coU-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta ampbipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
- Other preferred fragments are biologically active fragments.
- Biologically active fragments are those that mediate HOQBQ59 activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.
- polypeptide fragments retain the biological activity of the HOQBQ59, including antigenic activity.
- fragment having the amino acid sequence of SEQ ID NO: 4.
- Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions - i.e. , those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and De; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.
- the HOQBQ59 polypeptides of the invention can be prepared in any suitable manner.
- Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
- Polynucleotides of the Invention are well understood in the art.
- HOQBQ59 polynucleotides include isolated polynucleotides which encode the HOQBQ59 polypeptides and fragments, and polynucleotides closely related thereto. More specifically, HOQBQ59 polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:l encoding a HOQBQ59 polypeptide of SEQ ID NO: 2, and polynucleotides having the particular sequences of SEQ ID NOS: 1 and 3.
- HOQBQ59 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the HOQBQ59 polypeptide of SEQ ID NO:2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1 over its entire length.
- polynucleotides at least 90% identical are particularly preferred, and those with at least 95 % are especially preferred.
- those with at least 97 % are highly preferred and those with at least 98-99 % are most highly preferred, with at least 99 % being the most preferred.
- HOQBQ59 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:l to hybridize under conditions useable for amplification or for use as a probe or marker.
- the invention also provides polynucleotides which are complementary to such HOQBQ59 polynucleotides.
- HOQBQ59 of the invention is structurally related to other proteins of the RNA processing family, as shown by the results of sequencing the cDNA encoding human HOQBQ59.
- the cDNA sequence of SEQ ID NO: 1 contains an open reading frame (nucleotide number 289 to 939) encoding a polypeptide of 217 amino acids of SEQ ID NO: 2.
- the amino acid sequence of Table 1 (SEQ ID NO:2) has about 60% identity (using GAPGCG) in 109 amino acid residues with YHR089c (GAR1) of 5. cerevisiae (Genbank accession numer: X63617).
- the nucleotide sequence of Table 1 (SEQ ID NO: 1) has about 62% identity (using BLAST) in 171 nucleotide residues with YHR089c (GAR1) of 5. cerevisiae (Genbank accession numer: X63617).
- HOQBQ59 polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.
- a nucleotide sequence of a human HOQBQ59 (SEQ ID NO: 1).
- One polynucleotide of the present invention encoding HOQBQ59 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human Jurkat T-cell Gl phase; Bone Marrow Cell Line (RS4;11); Jurkat T-Cell, S phase; Human (HCC) cell line liver (mouse) metastasis; Human OB HOS treated (1 nM E2) fraction I; Human Lung; Liver HepG2 cell line; Human Fetal Epithelium; Macrophage (GM-CSF treated); Helper T cell, II; Helper T Cell, I; Activated T-Cells (12 hrs, re-excision); using the expressed sequence tag (EST) analysis (Adams, M.D., et al.
- EST expressed sequence tag
- Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
- nucleotide sequence encoding HOQBQ59 polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 289 to 939 of SEQ ID NO: 1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.
- the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions.
- a marker sequence which facilitates purification of the fused polypeptide can be encoded.
- the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al. , Proc NatlAcad Sci USA (1989) 86:821-824, or is an HA tag.
- the polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
- polynucleotides encoding HOQBQ59 variants comprising the amino acid sequence of HOQBQ59 polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination.
- Table 3 SEQ ID NO: 3
- SEQ ID NO: 4 amino acid sequence of Table 4
- a partial nucleotide sequence of a human HOQBQ59 (SEQ ID NO: 3).
- a partial amino acid sequence of a human HOQBQ59 (SEQ ID NO: 4).
- the present invention further relates to polynucleotides that hybridize to the herein above-described sequences.
- the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides.
- stringent conditions means hybridization will occur only if there is at least 80 % , and preferably at least 90 % , and more preferably at least 95 % , yet even more preferably 97-99 % identity between the sequences.
- Polynucleotides of the invention which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO: 3), may be used as hybridization probes for cDNA and genomic DNA, to isolate full- length cDNAs and genomic clones encoding HOQBQ59 polypeptide and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the HOQBQ59 gene.
- Such hybridization techniques are known to those of skill in the art.
- these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95 % identical to that of the referent.
- the probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.
- to obtain a polynucleotide encoding HOQBQ59 polypeptide, including homologs and orthologs from species other than human comprises the steps of screening an appropriate library under stingent hybridization conditions with a labeled probe having the SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO: 3), and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art.
- HOQBQ59 polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridize under stringent condition to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO:3). Also included with HOQBQ59 polypeptides are polypeptide comprising amino acid sequence encoded by nucleotide sequence obtained by the above hybridization condition.
- Stringent hybridization conditions are as defined above or, alternatively, conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.
- polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease.
- the present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques.
- Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
- host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention.
- Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al. , BASIC METHODS IN MOLECULAR BIOLOGY (1986) and Sambrook et al. , MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
- bacterial cells such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Aspergillus cells
- insect cells such as Drosophil S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
- plant cells include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells
- fungal cells such as yeast cells and Aspergillus cells
- insect cells such as Drosophil S2 and Spodoptera Sf9 cells
- animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells
- Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.
- viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses
- vectors derived from combinations thereof such as those derived from plasmid and bacteriophage genetic elements, such as cosmid
- the expression systems may contain control regions that regulate as well as engender expression.
- any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used.
- the appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al. , MOLECULAR CLONING, A LABORATORY MANUAL (supra).
- secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
- the polypeptide be produced at the surface of the cell.
- the cells may be harvested prior to use in the screening assay. If HOQBQ59 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered.
- HOQBQ59 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
- This invention also relates to the use of HOQBQ59 polynucleotides for use as diagnostic reagents. Detection of a mutated form of HOQBQ59 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of HOQBQ59. Individuals carrying mutations in the HOQBQ59 gene may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material.
- the genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis.
- RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled HOQBQ59 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g. , Myers et al.
- an array of oligonucleotides probes comprising HOQBQ59 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g. , genetic mutations.
- Array technology methods are well known and have general applicabiUty and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability.
- the diagnostic assays offer a process for diagnosing or determining a susceptibility to bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, man
- bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, can be diagnosed
- Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.
- Assay techniques that can be used to determine levels of a protein, such as an HOQBQ59 polypeptide, in a sample derived from a host are well-known to those of skill in the art.
- Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and FT ISA assays.
- the present invention relates to a diagonostic kit for a disease or suspectability to a disease, particularly bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesi
- HOQBQ59 polypeptide preferably the polypeptide of SEQ ID NO: 2, or a fragment thereof; or (d) an antibody to a HOQBQ59 polypeptide, preferably to the polypeptide of SEQ ID NO:
- the nucleotide sequences of the present invention are also valuable for chromosome identification.
- the sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome.
- the mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library).
- genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).
- linkage analysis coinheritance of physically adjacent genes.
- the differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.
- polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the HOQBQ59 polypeptides.
- immunospecific means that the antibodies have substantiall greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
- Antibodies generated against the HOQBQ59 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols.
- any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C, Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al. , Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al. , MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).
- Antibodies against HOQBQ59 polypeptides may also be employed to treat bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (TBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton
- Vaccines Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with HOQBQ59 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris;
- Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering HOQBQ59 polypeptide via a vector directing expression of HOQBQ59 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.
- composition which, when introduced into a mammalian host, induces an immunological response in that mammal to a HOQBQ59 polypeptide wherein the composition comprises a HOQBQ59 polypeptide or HOQBQ59 gene.
- the vaccine formulation may further comprise a suitable carrier. Since HOQBQ59 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection).
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
- the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation. Screening Assays
- the HOQBQ59 polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the HOQBQ59 polypeptide of the present invention.
- polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures.
- These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors, etc. , as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan et al. , Current Protocols in Immunology l(2):Chapter 5 (1991).
- HOQBQ59 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drags which stimulate HOQBQ59 polypeptide on the one hand and which can inhibit the function of HOQBQ59 polypeptide on the other hand.
- agonists are employed for therapeutic and prophylactic purposes for such conditions as bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease
- Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (EBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's
- such screening procedures may involve using appropriate cells which express the HOQBQ59 polypeptide or respond to HOQBQ59 polypeptide of the present invention.
- Such cells include cells from mammals, yeast, Drosophila or E. coli.
- Cells which express the HOQBQ59 polypeptide (or cell membrane containing the expressed polypeptide) or respond to HOQBQ59 polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.
- the ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for HOQBQ59 activity.
- the assays may simply test binding of a candidate compound wherein adherence to the cells bearing the HOQBQ59 polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the HOQBQ59 polypeptide, using detection systems appropriate to the cells bearing the HOQBQ59 polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
- the assays may simply comprise the steps of mixing a candidate compound with a solution containing a HOQBQ59 polypeptide to form a mixture, measuring HOQBQ59 activity in the mixture, and comparing the HOQBQ59 activity of the mixture to a standard.
- the HOQBQ59 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of HOQBQ59 mRNA and protein in cells.
- an ELISA may be constructed for measuring secreted or cell associated levels of HOQBQ59 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of HOQBQ59 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
- the HOQBQ59 protein may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the HOQBQ59 is labeled with a radioactive isotope (eg 1251), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy.
- a radioactive isotope eg 1251
- chemically modified eg biotinylated
- these binding assays can be used to identify agonists and antagonists of HOQBQ59 which compete with the binding of HOQBQ59 to its receptors, if any. Standard methods for conducting screening assays are well understood in the art.
- HOQBQ59 polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, enzymes, receptors, etc., as the case may be, of the HOQBQ59 polypeptide, e.g., a fragment of the ligands, substrates, enzymes, receptors, etc. ; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
- the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for HOQBQ59 polypeptides; or compounds which decrease or enhance the production of HOQBQ59 polypeptides, which comprises:
- kits may comprise a substantial component.
- This invention provides methods of treating abnormal conditions such as, bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tour
- One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the HOQBQ59 polypeptide, such as, for example, by blocking the binding of hgands, substrates, enzymes, receptors, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
- an inhibitor compound as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the HOQBQ59 polypeptide, such as, for example, by blocking the binding of hgands, substrates, enzymes, receptors, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition.
- HOQBQ59 polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous HOQBQ59 polypeptide may be administered.
- Typical embodiments of such competitors comprise fragments of the HOQBQ59 polypeptide.
- soluble forms of HOQBQ59 polypeptides still capable of binding the ligand in competition with endogenous HOQBQ59 polypeptide may be administered.
- Typical embodiments of such competitors comprise fragments of the HOQBQ59 polypeptide.
- expression of the gene encoding endogenous HOQBQ59 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered.
- HOQBQ59 For treating abnormal conditions related to an under-expression of HOQBQ59 and its activity, several approaches are also available.
- One approach comprises administering to a subject a therapeutically effective amount of a compound which activates HOQBQ59 polypeptide, i.e. , an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.
- gene therapy may be employed to effect the endogenous production of HOQBQ59 by the relevant cells in the subject.
- a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above.
- the retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest.
- These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo.
- Another approach is to administer a therapeutic amount of HOQBQ59 polypeptides in combination with a suitable pharmaceutical carrier.
- Peptides such as the soluble form of HOQBQ59 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier.
- suitable pharmaceutical carrier include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art.
- the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
- Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
- systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection.
- Other injection routes such as subcutaneous, intramuscular, or intraperitoneal, can be used.
- Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents.
- oral administration may also be possible.
- Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like. The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner.
- Suitable dosages are in the range of 0.1-100 ⁇ g/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.
- Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above.
- cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.
- a polynucleotide such as a DNA or RNA
- RACE Rapid Amplification of cDNA Ends
- the polymerase chain reaction can be used to amplify the 5' end of the cDNA from human cDNA libraries using sequential rounds of 'nested' PCR with two sets of primers.
- One set of antisense primers is specific to the 5 ' end of the partial cDNA and the other set of primers anneals to vector specific sequence.
- the amplified products are cloned into an appropriate vector and subjected to restriction and sequence analysis.
- Val Asp Glu lie Phe Gly Gin Leu Arg Asp Phe Tyr Phe Ser Val Lys 115 120 125
- Tyr lie Asp Pro Tyr Lys Leu Leu Pro Leu Gin Arg Phe Leu Pro Arg 145 150 155 160 Pro Pro Gly Glu Lys Gly Pro Pro Pro Arg Gly Gly Gly Arg Gly Gly Arg
- AAGCAACACT GGTTCCAAAA CAGCCTTTAG CGCTGGAAAA GTGGCAATAA TAGATAACCT 1200
- MOLECULE TYPE protein
- SEQUENCE DESCRIPTION SEQ ID NO: :
- Ser Ser Phe Lys Lys Leu Gin Lys Phe Tyr lie Asp Pro Tyr Lys Leu 50 55 60 Leu Pro Leu Gin Arg Phe Leu Pro Arg Pro Pro Gly Glu Lys Gly Pro 65 70 75 80
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
HOQBQ59 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HOQBQ59 polypeptides and polynucleotides in the design of protocols for the treatment of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others, and diagnostic assays for such conditions.
Description
HOQBQ59
This apphcation claims the benefit of U.S. Provisional Application No. 60/052,009, filed July 9, 1997.
FIELD OF INVENTION This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the RNA processing family, hereinafter referred to as HOQBQ59. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides. BACKGROUND OF THE INVENTION
Evolutionary conservation of homologous gene products from distantly related organisms provides an information resource of great value for elucidating protein structure and function. Subregions of high sequence similarity found in proteins that have diverged over long periods of evolutionary time highlight domains within proteins that are of greatest stractural and/or functional significance. A better understanding of a human protein' s function can be gained by drawing upon the biological information known about related proteins from other species such as S. cerevisiae. The most stringent definition of homology between two genes is statistically significant sequence similarity accompanied by functional complementation. There are a number of cases where expression of a human cDNA in vivo can complement a mutation in the homologous S. cerevisiae gene. In other cases, although the human gene is highly similar in sequence, it is unable to complement the yeast mutation. Nevertheless, these genes may be considered orthologs or functional homologs if they are known to perform the same functions in their respective organisms.
RNA processing is a fundamental biological process for all eukaryotic cells. All types of pre-RNAs (pre-tRNA, pre-mRNA, and pre-rRNA) are processed post-transcriptionally. In yeast, tRNA processing is carried out by a complex whose catalytic subunit is encoded by SEN2; mRNA processing is carried out by a complex (the splicesome), which contains both proteins and RNAs; and rRNA is processed in the nucleolus by snRNPS (small nuclear ribonuclear proteins which consist of proteins and snoRNAs). A yeast protein involved in
RNA processing, NOP1, can be complemented by its human homolog, fibrillarin. A number of yeast proteins have been found to be similar to Noplp based on sequence homology. These proteins all contain WD-40 repeats which are also contained in beta-subunits of trimeric G- proteins. Deficiencies in pre-mRNA splicing can result in aberrant message expression and decreased levels of expression of processed mRNA. Many genetic diseases, such as Gauchers disease, Alzheimer's disease, and cancer have been mapped to mutations which result in incorrect splicing. The resulting mRNAs then code for proteins which are either nonfunctional or have an altered function. Mutations in genes which are required for efficient processing of pre-mRNA may similarly be expected to effect gene expression.
This indicates that the RNA processing family has an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of the RNA processing family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (HBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HIV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to HOQBQ59 polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such HOQBQ59 polypeptides and polynucleotides. Such uses include the treatment
of bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (TBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with HOQBQ59 imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate HOQBQ59 activity or levels.
DESCRIPTION OF THE INVENTION
Definitions
The following definitions are provided to facilitate understanding of certain terms used frequently herein. "HOQBQ59" refers, among others, generally to a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 or an allelic variant thereof.
"HOQBQ59 activity or HOQBQ59 polypeptide activity" or "biological activity of the HOQBQ59 or HOQBQ59 polypeptide" refers to the metabolic or physiologic function of said HOQBQ59 including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said HOQBQ59.
"HOQBQ59 gene" refers to a polynucleotide having the nucleotide sequence set forth in SEQ ID NO:l or allelic variants thereof and/or their complements.
" Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.
"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double- stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e. , peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.
" Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side- chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993 and Wold, F. , Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al. , "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182:626-646 and Rattan et al. , "Protein Synthesis: Posttranslational Modifications and Aging", Ann NY Acad Sci (1992) 663:48-62.
"Variant" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential
properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.
"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, e.g. : (COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING:
INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., SLAM J Applied Math (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop,
ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., SIAMJ Applied Math (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCS program package (Devereux, J. , et al. , Nucleic Acids Research (1984) 12(1):387), BLASTP, BLASTN, FASTA (Atschul, S.F. et al. , J Molec Biol (1990) 215:403).
As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95 % "identity" to a reference nucleotide sequence of SEQ ID NO: 1 is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95 % identical to a reference nucleotide sequence, up to 5 % of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5 % of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Similarly, by a polypeptide having an amino acid sequence having at least, for example, 95% "identity" to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95 % identical to a reference amino acid sequence, up to 5 % of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5 % of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between
those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.
Polypeptides of the Invention
In one aspect, the present invention relates to HOQBQ59 polypeptides (or HOQBQ59 proteins) . The HOQBQ59 polypeptides include the polypeptide of SEQ ID NOS: 2 and 4; as well as polypeptides comprising the amino acid sequence of SEQ ID NO: 2; and polypeptides comprising the amino acid sequence which have at least 80% identity to that of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and even still more preferably at least 95 % identity to SEQ ID NO: 2. Furthermore, those with at least 97-99% are highly preferred. Also included within
HOQBQ59 polypeptides are polypeptides having the amino acid sequence which have at least 80% identity to the polypeptide having the amino acid sequence of SEQ ID NO:2 over its entire length, and still more preferably at least 90% identity, and still more preferably at least 95 % identity to SEQ ID NO:2. Furthermore, those with at least 97- 99% are highly preferred. Preferably HOQBQ59 polypeptide exhibit at least one biological activity of HOQBQ59.
The HOQBQ59 polypeptides may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro- sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.
Fragments of the HOQBQ59 polypeptides are also included in the invention. A fragment is a polypeptide having an amino acid sequence that entirely is the same as part, but not all, of the amino acid sequence of the aforementioned HOQBQ59 polypeptides. As with HOQBQ59 polypeptides, fragments may be "free-standing, " or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, and 101 to the end of HOQBQ59 polypeptide. In this context "about" includes the particularly
recited ranges larger or smaller by several, 5, 4, 3, 2 or 1 amino acid at either extreme or at both extremes.
Preferred fragments include, for example, truncation polypeptides having the amino acid sequence of HOQBQ59 polypeptides, except for deletion of a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus or deletion of two continuous series of residues, one including the amino terminus and one including the carboxyl teraiinus. Also preferred are fragments characterized by stractural or functional attributes such as fragments that comprise alpha-helix and alpha- helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coU-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta ampbipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Other preferred fragments are biologically active fragments. Biologically active fragments are those that mediate HOQBQ59 activity, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those that are antigenic or immunogenic in an animal, especially in a human.
Preferably, all of these polypeptide fragments retain the biological activity of the HOQBQ59, including antigenic activity. Among the most preferred fragment is that having the amino acid sequence of SEQ ID NO: 4. Variants of the defined sequence and fragments also form part of the present invention. Preferred variants are those that vary from the referents by conservative amino acid substitutions - i.e. , those that substitute a residue with another of like characteristics. Typical such substitutions are among Ala, Val, Leu and De; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination.
The HOQBQ59 polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
Polynucleotides of the Invention
Another aspect of the invention relates to HOQBQ59 polynucleotides. HOQBQ59 polynucleotides include isolated polynucleotides which encode the HOQBQ59 polypeptides and fragments, and polynucleotides closely related thereto. More specifically, HOQBQ59 polynucleotide of the invention include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:l encoding a HOQBQ59 polypeptide of SEQ ID NO: 2, and polynucleotides having the particular sequences of SEQ ID NOS: 1 and 3. HOQBQ59 polynucleotides further include a polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the HOQBQ59 polypeptide of SEQ ID NO:2, and a polynucleotide comprising a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1 over its entire length. In this regard, polynucleotides at least 90% identical are particularly preferred, and those with at least 95 % are especially preferred. Furthermore, those with at least 97 % are highly preferred and those with at least 98-99 % are most highly preferred, with at least 99 % being the most preferred. Also included under HOQBQ59 polynucleotides are a nucleotide sequence which has sufficient identity to a nucleotide sequence contained in SEQ ID NO:l to hybridize under conditions useable for amplification or for use as a probe or marker. The invention also provides polynucleotides which are complementary to such HOQBQ59 polynucleotides.
HOQBQ59 of the invention is structurally related to other proteins of the RNA processing family, as shown by the results of sequencing the cDNA encoding human HOQBQ59. The cDNA sequence of SEQ ID NO: 1 contains an open reading frame (nucleotide number 289 to 939) encoding a polypeptide of 217 amino acids of SEQ ID NO: 2. The amino acid sequence of Table 1 (SEQ ID NO:2) has about 60% identity (using GAPGCG) in 109 amino acid residues with YHR089c (GAR1) of 5. cerevisiae (Genbank accession numer: X63617). The nucleotide sequence of Table 1 (SEQ ID NO: 1) has about 62% identity (using BLAST) in 171 nucleotide residues with YHR089c (GAR1) of 5. cerevisiae (Genbank accession numer: X63617). Thus, HOQBQ59 polypeptides and polynucleotides of the present invention are expected to have, inter alia, similar biological functions/properties to their homologous polypeptides and polynucleotides, and their utility is obvious to anyone skilled in the art.
Table 1-
1 TCGGCACGAG CGTCAGGCAA GTTGGCCTcT cTGTTGTAAA TTAgTGGTTA
51 AGgTTATCTA TTATTgCCAC TTTTCCAGCG cTAAAGGCTG TTTTGGAACC
101 AGTGTTGCTT GTTCCGCGGG TGATTGGCTT TTTTTTTTTG GCAAACCAGT
151 TATTCAAGTT TCTGGTCTTT AAAAAACTCT GTGGCGgTAC GGTAACCGAG
201 GAGGTTCCAG CGCGGCGGAA GTACCCCGCG GGTGGGTGTG TGCGCAAGGC
251 CAGGGCCAGA GGGGCACGTG GCGCCGGGAG GAGAGAGAAT GTCTTTTCGA
301 GGCGGAGGTC GTGGAGGCTT TAATCGAGGT GGTGGAGGTG GCGGCTTCAA
351 CCGAGGCGGC AGCAGCAACC ACTTCCGAGG TGGAGGCGGC GGTGGAGGCG
401 GCGG(AATTT CAGAGGCGGC GGCAGGGGAG GATTTGGACG AGGGGGTGGC
451 CGCGGAGGCT TTAACAAAGG CCAAGACCAA GGACCTCCAG AACGTGTAGT
501 CTTATTAGGA GAGTTCCTGC ATCCCTGTGA AGATGACATA GTTTGTAAAT
551 GTACCACAGA TGAAAATAAG GTGCCTTATT TCAATGCTCC TGTTTACTTA
601 GAAAACAAAG AACAAATTGG AAAAGTGGAT GAAATATTTG GACAACTCAG
651 AGATTTTTAT TTTTCAGTTA AGTTGTCAGA AAACATGAAG GCTTCATCCT
701 TTAAAAAACT ACAGAAGTTT TATATAGACC CATATAAGCT GCTGCCACTG
751 CAGAGGTTTT TACCTCGACC TCCAGGTGAG AAAGGACCTC CAAGAGGTGG
801 TGGCAGGGGA GGCCGAGGAG GAGGAAGAGG AGGAGGTGGC AGAGGTGGTG
851 GCAGAGGCGG TGGTTTTAGA GGTGGAAGAG GAGGTGGAGG TGGGGGCTTC
901 AGAGGAGGAA GAGGTGGTGG TTTCAGAGGG AGAGGACATT AAGTGAAACA
951 GCTGACAGAC ATCACCAGTT GACTTcTGCA TTAACCTGCA TGATCTGTTT
1001 CTACTATGGA TTGGAAACTT GTTTCTTGAA CAAGTCTTGA AGATC
A nucleotide sequence of a human HOQBQ59 (SEQ ID NO: 1).
Table 2~
1 MSFRGGGRGG FNRGGGGGGF RGGSSNHFR GGGGGGGGGN FRGGGRGGFG
51 RGGGRGGFNK GQDQGPPERV VLLGEFLHPC EDDIVCKCTT DENKVPYFNA
101 PVYLENKEQI GKVDEIFGQL RDFYFSVKLS ENMKASSFKK LQKFYIDPYK
151 LLPLQRFLPR PPGEKGPPRG GGRGGRGGGR GGGGRGGGRG GGFRGGRGGG 201 GGGFRGGRGG GFRGRGH b An amino acid sequence of a human HOQBQ59 (SEQ ID NO: 2).
One polynucleotide of the present invention encoding HOQBQ59 may be obtained using standard cloning and screening, from a cDNA library derived from mRNA in cells of human Jurkat T-cell Gl phase; Bone Marrow Cell Line (RS4;11); Jurkat T-Cell, S phase; Human (HCC) cell line liver (mouse) metastasis; Human OB HOS treated (1 nM E2) fraction I; Human Lung; Liver HepG2 cell line; Human Fetal Epithelium; Macrophage (GM-CSF treated); Helper T cell, II; Helper T Cell, I; Activated T-Cells (12 hrs, re-excision); using the expressed sequence tag (EST) analysis (Adams, M.D., et al. Science (1991) 252:1651- 1656; Adams, M.D. et al. , Nature, (1992) 355:632-634; Adams, M.D., et al. , Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.
The nucleotide sequence encoding HOQBQ59 polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in Table 1 (nucleotide number 289 to 939 of SEQ ID NO: 1), or it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2.
When the polynucleotides of the invention are used for the recombinant production of HOQBQ59 polypeptide, the polynucleotide may include the coding sequence for the mature polypeptide or a fragment thereof, by itself; the coding sequence for the mature polypeptide or fragment in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al. , Proc NatlAcad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed,
non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.
Further preferred embodiments are polynucleotides encoding HOQBQ59 variants comprising the amino acid sequence of HOQBQ59 polypeptide of Table 2 (SEQ ID NO:2) in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acid residues are substituted, deleted or added, in any combination. Among the preferred polynucleotides of the present invention is contained in Table 3 (SEQ ID NO: 3) encoding the amino acid sequence of Table 4 (SEQ ID NO: 4).
Table 3£
1 TTAAGGGGAA TAAAACACTT TATTTTAAAA ATTCAAATTA TCCTTCAAAT
51 GAAAACTCCT ATCCATTTAT TGAGCACCCA CAGAGTGCCA GGCACTGTAC
101 AAAACATTAG AAAGACTTGT TCATGCTCTT TTAGAGCNAA ATTCACTATT
151 CCGTTGCACT TTGCATGATG CTGA(2ATTTT AGATCCATTG TCATAAAATG
201 ACCAAGATCT TCAAGACTTG TTCAAGAAAC AAGTTTCCAA TCCATAGTAG
251 AAACAGATCA TGCAGGTTAA TGCAGAAGTC AACTGGTGAT GTCTGTCAAC
301 TGTTTCACTT AATGTCCTCT CCCTCTGAAA CCACCACCTC TTCCTCCTCT
351 GAAGCCCCCA CCTCCACCTC CTCTTCCACC TCTAAAACCA CCGCCTCTGC
401 CACCACCTCT GCCACCTCCT CCTCTTCCTC CTCCTCGGCC TCCCCTGCCA
451 CCACCTCTTG GAGGTCCTTT CTCACCTGGA GGTCGAGGTA AAAACCTCTG
501 CAGTGGCAGC AGCTTATATG GGTCTATATA AAACTTCTGT AGTTTTTTAA
551 AGGATGAAGC CTTCATGTTT TCTGACAACT TAACTGAAAA ATAAAAATCT
601 CTGAGTTGTC CAAATATTTC CTCCACTTTT CCAATTTGTT CTTTGTTTTC
651 TAAGTAAACA GGAGCATTGA AATAAGGCAC CTTATTTTCA TCTGTGGTAC
701 ATTTACAAAC TATGTCATCT TCACAGGGAT GCAGGAACTC TCCTAATAAG
751 ACTACACGTT CTGGAGGTCC TTGGTCTTGG CCTTTGTTAA AGCCTCCGCG
801 GCCACCCCCT CGTCCAAATC CTCCCCTGCC GCCGCCTCTG AAATTGCCGC
851 CGCCTCCACC GCCGCCTCCA CCTCGGAAGT GGTTGCTGCT GCCACCTCGG
901 TTGAAGCCGC CACCTCCACC ACCTCGATTA AAGCCTCCAC GACCTCCGCC
951 TCGAAAAGAC ATTCTCTCTC CTCCCGGCGC CACGTGCCCC TCTGGCCCTG
1001 GCCTTGCGCA CACACCCACC CGCGGGGTAC TTCCGCCGCG CTGGAACCTC 1051 CTCGGTTACC GTACCGCCAC AGAG'I ΓΎTT AAAGACCAGA AACTTGAATA
1101 ACTGGTTTGC CAAAAAAAAA AAGCCAATCA CCCGCGGAAC AAGCAACACT
1151 GGTTCCAAAA CAGCCTTTAG CGCTGGAAAA GTGGCAATAA TAGATAACCT
1201 TAACCACTAA TTTACAACAG AGAGGCCAAC TTGCCTGACG NCTCTGCC
A partial nucleotide sequence of a human HOQBQ59 (SEQ ID NO: 3).
Table 4
CTTDEKΓKVPYFKIAPVYLENKEQIGKVEEIFGQLRDFYFSV PYKLLPLQRFLPRPPGEKGPPRGGGRGGRGGGRGGGGRGGGRGGGFRGGRGGGGGGFRGG GGGRGGF RGGGGGGFNRGGSSNHFRGGGGGGGGGNFRGGGRGGFGRGGGRGGFNKGQDQ GPPERWLLGEFLHPCEDDIVCK
A partial amino acid sequence of a human HOQBQ59 (SEQ ID NO: 4).
The present invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the present invention especially relates to polynucleotides which hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the term "stringent conditions" means hybridization will occur only if there is at least 80 % , and preferably at least 90 % , and more preferably at least 95 % , yet even more preferably 97-99 % identity between the sequences.
Polynucleotides of the invention, which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO: 3), may be used as hybridization probes for cDNA and genomic DNA, to isolate full- length cDNAs and genomic clones encoding HOQBQ59 polypeptide and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to the HOQBQ59 gene. Such hybridization techniques are known to those of skill in the art. Typically these nucleotide sequences are 80% identical, preferably 90% identical, more preferably 95 % identical to that of the referent. The probes generally will comprise at least 15 nucleotides. Preferably, such probes will have at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will range between 30 and 50 nucleotides.
In one embodiment, to obtain a polynucleotide encoding HOQBQ59 polypeptide, including homologs and orthologs from species other than human, comprises the steps of screening an appropriate library under stingent hybridization conditions with a labeled probe having the SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO: 3), and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to those of skill in the art. Thus in another aspect, HOQBQ59 polynucleotides of the present invention further include a nucleotide sequence comprising a nucleotide sequence that hybridize under stringent condition to a nucleotide sequence having SEQ ID NO: 1 or a fragment thereof (including that of SEQ ID NO:3). Also included with HOQBQ59 polypeptides are polypeptide comprising amino acid sequence encoded by nucleotide sequence obtained by the above hybridization condition. Stringent hybridization conditions are as defined above or, alternatively, conditions under overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in O.lx SSC at about 65°C.
The polynucleotides and polypeptides of the present invention may be employed as research reagents and materials for discovery of treatments and diagnostics to animal and human disease. Vectors, Host Cells, Expression
The present invention also relates to vectors which comprise a polynucleotide or polynucleotides of the present invention, and host cells which are genetically engineered with vectors of the invention and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al. , BASIC METHODS IN MOLECULAR
BIOLOGY (1986) and Sambrook et al. , MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) such as calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.
Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, E. coli, Streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophil S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.
A great variety of expression systems can be used. Such systems include, among others, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al. , MOLECULAR CLONING, A LABORATORY MANUAL (supra).
For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the desired polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
If the HOQBQ59 polypeptide is to be expressed for use in screening assays, generally, it is preferred that the polypeptide be produced at the surface of the cell. In this event, the
cells may be harvested prior to use in the screening assay. If HOQBQ59 polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide; if produced intracellularly, the cells must first be lysed before the polypeptide is recovered. HOQBQ59 polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.
Diagnostic Assays
This invention also relates to the use of HOQBQ59 polynucleotides for use as diagnostic reagents. Detection of a mutated form of HOQBQ59 gene associated with a dysfunction will provide a diagnostic tool that can add to or define a diagnosis of a disease or susceptibility to a disease which results from under-expression, over-expression or altered expression of HOQBQ59. Individuals carrying mutations in the HOQBQ59 gene may be detected at the DNA level by a variety of techniques. Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled HOQBQ59 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing.
See, e.g. , Myers et al. , Science (1985) 230: 1242. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method. See Cotton et al. , Proc Natl Acad Sci USA (1985) 85: 4397-4401. In another embodiment, an array of oligonucleotides probes comprising HOQBQ59 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g. , genetic mutations. Array technology methods are well known and have general applicabiUty and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability. (See for example: M.Chee et al, Science, Vol 274, pp 610-613 (1996)). The diagnostic assays offer a process for diagnosing or determining a susceptibility to bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome through detection of mutation in the HOQBQ59 gene by the methods described.
In addition, bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic
hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, can be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of HOQBQ59 polypeptide or HOQBQ59 mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as an HOQBQ59 polypeptide, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and FT ISA assays.
Thus in another aspect, the present invention relates to a diagonostic kit for a disease or suspectability to a disease, particularly bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, which comprises: (a) a HOQBQ59 polynucleotide, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
(b) a nucleotide sequence complementary to that of (a);
(c) a HOQBQ59 polypeptide, preferably the polypeptide of SEQ ID NO: 2, or a fragment thereof; or
(d) an antibody to a HOQBQ59 polypeptide, preferably to the polypeptide of SEQ ID NO:
2.
It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Chromosome Assays
The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. Antibodies
The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them can also be used as immunogens to produce antibodies immunospecific for the HOQBQ59 polypeptides. The term "immunospecific" means that the antibodies have substantiall greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.
Antibodies generated against the HOQBQ59 polypeptides can be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be
used. Examples include the hybridoma technique (Kohler, G. and Milstein, C, Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al. , Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al. , MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).
Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms including other mammals, may be used to express humanized antibodies. The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.
Antibodies against HOQBQ59 polypeptides may also be employed to treat bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (TBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, among others.
Vaccines Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with HOQBQ59 polypeptide, or a fragment thereof, adequate to produce antibody and/or T cell immune response to protect said animal from bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis,
Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, among others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering HOQBQ59 polypeptide via a vector directing expression of HOQBQ59 polynucleotide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases.
Further aspect of the invention relates to an immunological vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a HOQBQ59 polypeptide wherein the composition comprises a HOQBQ59 polypeptide or HOQBQ59 gene. The vaccine formulation may further comprise a suitable carrier. Since HOQBQ59 polypeptide may be broken down in the stomach, it is preferably administered parenterally (including subcutaneous, intramuscular, intravenous, intradermal etc. injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
Screening Assays
The HOQBQ59 polypeptide of the present invention may be employed in a screening process for compounds which activate (agonists) or inhibit activation of (antagonists, or otherwise called inhibitors) the HOQBQ59 polypeptide of the present invention. Thus, polypeptides of the invention may also be used to assess identify agonist or antagonists from, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These agonists or antagonists may be natural or modified substrates, ligands, enzymes, receptors, etc. , as the case may be, of the polypeptide of the present invention; or may be structural or functional mimetics of the polypeptide of the present invention. See Coligan et al. , Current Protocols in Immunology l(2):Chapter 5 (1991).
HOQBQ59 polypeptides are responsible for many biological functions, including many pathologies. Accordingly, it is desirous to find compounds and drags which stimulate HOQBQ59 polypeptide on the one hand and which can inhibit the function of HOQBQ59 polypeptide on the other hand. In general, agonists are employed for therapeutic and prophylactic purposes for such conditions as bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome. Antagonists may be employed for a variety of therapeutic and prophylactic purposes for such conditions as bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (EBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; HIV-associated cachexia and
other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome.
In general, such screening procedures may involve using appropriate cells which express the HOQBQ59 polypeptide or respond to HOQBQ59 polypeptide of the present invention. Such cells include cells from mammals, yeast, Drosophila or E. coli. Cells which express the HOQBQ59 polypeptide (or cell membrane containing the expressed polypeptide) or respond to HOQBQ59 polypeptide are then contacted with a test compound to observe binding, or stimulation or inhibition of a functional response. The ability of the cells which were contacted with the candidate compounds is compared with the same cells which were not contacted for HOQBQ59 activity.
The assays may simply test binding of a candidate compound wherein adherence to the cells bearing the HOQBQ59 polypeptide is detected by means of a label directly or indirectly associated with the candidate compound or in an assay involving competition with a labeled competitor. Further, these assays may test whether the candidate compound results in a signal generated by activation of the HOQBQ59 polypeptide, using detection systems appropriate to the cells bearing the HOQBQ59 polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.
Further, the assays may simply comprise the steps of mixing a candidate compound with a solution containing a HOQBQ59 polypeptide to form a mixture, measuring HOQBQ59 activity in the mixture, and comparing the HOQBQ59 activity of the mixture to a standard.
The HOQBQ59 cDNA, protein and antibodies to the protein may also be used to configure assays for detecting the effect of added compounds on the production of
HOQBQ59 mRNA and protein in cells. For example, an ELISA may be constructed for measuring secreted or cell associated levels of HOQBQ59 protein using monoclonal and polyclonal antibodies by standard methods known in the art, and this can be used to discover agents which may inhibit or enhance the production of HOQBQ59 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.
The HOQBQ59 protein may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the HOQBQ59 is labeled with a radioactive isotope (eg 1251), chemically modified (eg biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. In addition to being used for purification and cloning of the receptor, these binding assays can be used to identify agonists and antagonists of HOQBQ59 which compete with the binding of HOQBQ59 to its receptors, if any. Standard methods for conducting screening assays are well understood in the art.
Examples of potential HOQBQ59 polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, enzymes, receptors, etc., as the case may be, of the HOQBQ59 polypeptide, e.g., a fragment of the ligands, substrates, enzymes, receptors, etc. ; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.
Thus in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for HOQBQ59 polypeptides; or compounds which decrease or enhance the production of HOQBQ59 polypeptides, which comprises:
(a) a HOQBQ59 polypeptide, preferably that of SEQ ID NO:2;
(b) a recombinant cell expressing a HOQBQ59 polypeptide, preferably that of SEQ ID NO:2;
(c) a cell membrane expressing a HOQBQ59 polypeptide; preferably that of SEQ ID NO:
2; or
(d) antibody to a HOQBQ59 polypeptide, preferably that of SEQ ID NO: 2.
It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.
Prophylactic and Therapeutic Methods
This invention provides methods of treating abnormal conditions such as, bone loss including osteoporosis; inflammatory diseases such as Adult Respiratory Disease Syndrome (ARDS), Rheumatoid arthritis, Osteoarthritis, Inflammatory Bowel Disease (IBD), psoriasis, dermatitis, asthma, allergies; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HTV-2; HlV-associated cachexia and other immunodeficiency disorders; septic shock; pain; injury; cancers including testicular cancer; anorexia; bulimia; Parkinson's disease; cardiovascular disease including restenosis, atherosclerosis, acute heart failure, myocardial infarction; hypotension; hypertension; urinary retention; angina pectoris; ulcers; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntmgton's disease or Gilles dela Tourett's syndrome, related to both an excess of and insufficient amounts of HOQBQ59 polypeptide activity. If the activity of HOQBQ59 polypeptide is in excess, several approaches are available.
One approach comprises administering to a subject an inhibitor compound (antagonist) as hereinabove described along with a pharmaceutically acceptable carrier in an amount effective to inhibit the function of the HOQBQ59 polypeptide, such as, for example, by blocking the binding of hgands, substrates, enzymes, receptors, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of
HOQBQ59 polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous HOQBQ59 polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the HOQBQ59 polypeptide.
In another approach, soluble forms of HOQBQ59 polypeptides still capable of binding the ligand in competition with endogenous HOQBQ59 polypeptide may be administered. Typical embodiments of such competitors comprise fragments of the HOQBQ59 polypeptide. In still another approach, expression of the gene encoding endogenous HOQBQ59 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered. See, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression. CRC Press, Boca Raton, FL (1988). Alternatively, oMgonucleotides which form triple heHces with the gene can be supplied. See, for example, Lee et al, Nucleic Acids Res (1979) 6:3073; Cooney et al, Science (1988) 241:456; Dervan et al, Science (1991) 251:1360. These oligomers can be administered per se or the relevant oligomers can be expressed in vivo.
For treating abnormal conditions related to an under-expression of HOQBQ59 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates HOQBQ59 polypeptide, i.e. , an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of HOQBQ59 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo and expression of the polypeptide in vivo. For overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of HOQBQ59 polypeptides in combination with a suitable pharmaceutical carrier.
Formulation and Administration
Peptides, such as the soluble form of HOQBQ59 polypeptides, and agonists and antagonist peptides or small molecules, may be formulated in combination with a suitable pharmaceutical carrier. Such formulations comprise a therapeutically effective amount of the polypeptide or compound, and a pharmaceutically acceptable carrier or excipient. Such carriers include but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. Formulation should suit the mode of administration, and is well within the skill of the art. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
Preferred forms of systemic administration of the pharmaceutical compositions include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if properly formulated in enteric or encapsulated formulations, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels and the like. The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 μg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.
Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for
example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.
Examples The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples illustrate, but do not limit the invention.
Example 1
While there are several methods to obtain the full length cDNA two are outlined below.
1.) The method of Rapid Amplification of cDNA Ends (RACE) can be utilized to obtain the 5' end. See Frohman et al., Proc. Nat. Acad. Sci USA 85, 8998-9002. (1988). Briefly, specific oliognucleotides are annealed to mRNA and used to prime the synthesis of the cDNA strand. Following destruction of the mRNA with RNaseH, a poly C anchor sequence is added to the 3 ' end of the cDNA and the resulting fragment is amplified using a 'nested' set of HLWAC81 antisense primers and an anchor sequence primer. The amplified fragment is cloned into an appropriate vector and subjected to restriction and sequence analysis.
2.) The polymerase chain reaction can be used to amplify the 5' end of the cDNA from human cDNA libraries using sequential rounds of 'nested' PCR with two sets of primers. One set of antisense primers is specific to the 5 ' end of the partial cDNA and the other set of primers anneals to vector specific sequence. The amplified products are cloned into an appropriate vector and subjected to restriction and sequence analysis.
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANT: DEMARINI, DOUGLAS (ii) TITLE OF THE INVENTION: HOQBQ59
(iii) NUMBER OF SEQUENCES: 4
(iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: RATNER & PRESTIA
(B) STREET: P.O. BOX 980
(C) CITY: VALLEY FORGE
(D) STATE: PA
(E) COUNTRY: USA (F) ZIP: 19482
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ for Windows Version 2.
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: TO BE ASSIGNED (B) FILING DATE: 12-N0V-1997
(C) CLASSIFICATION: UNKNOWN
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 60/052,009 (B) FILING DATE: 09-JUL-1997
(viii) ATTORNEY/AGENT INFORMATION: (A) NAME: PRESTIA, PAUL F
(B) REGISTRATION NUMBER: 23,031
(C) REFERENCE/DOCKET NUMBER: GH-70146
(ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 610-407-0700
(B) TELEFAX: 610-407-0701
(C) TELEX: 846169
(2) INFORMATION FOR SEQ ID NO:l;
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1045 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TCGGCACGAG CGTCAGGCAA GTTGGCCTCT CTGTTGTAAA TTAGTGGTTA AGGTTATCTA 60
TTATTGCCAC TTTTCCAGCG CTAAAGGCTG TTTTGGAACC AGTGTTGCTT GTTCCGCGGG 120
TGATTGGCTT TTTTTTTTTG GCAAACCAGT TATTCAAGTT TCTGGTCTTT AAAAAACTCT 180
GTGGCGGTAC GGTAACCGAG GAGGTTCCAG CGCGGCGGAA GTACCCCGCG GGTGGGTGTG 240
TGCGCAAGGC CAGGGCCAGA GGGGCACGTG GCGCCGGGAG GAGAGAGAAT GTCTTTTCGA 300 GGCGGAGGTC GTGGAGGCTT TAATCGAGGT GGTGGAGGTG GCGGCTTCAA CCGAGGCGGC 360
AGCAGCAACC ACTTCCGAGG TGGAGGCGGC GGTGGAGGCG GCGGCAATTT CAGAGGCGGC 420
GGCAGGGGAG GATTTGGACG AGGGGGTGGC CGCGGAGGCT TTAACAAAGG CCAAGACCAA 480
GGACCTCCAG AACGTGTAGT CTTATTAGGA GAGTTCCTGC ATCCCTGTGA AGATGACATA 540
GTTTGTAAAT GTACCACAGA TGAAAATAAG GTGCCTTATT TCAATGCTCC TGTTTACTTA 600 GAAAACAAAG AACAAATTGG AAAAGTGGAT GAAATATTTG GACAACTCAG AGATTTTTAT 660
TTTTCAGTTA AGTTGTCAGA AAACATGAAG GCTTCATCCT TTAAAAAACT ACAGAAGTTT 720
TATATAGACC CATATAAGCT GCTGCCACTG CAGAGGTTTT TACCTCGACC TCCAGGTGAG 780
AAAGGACCTC CAAGAGGTGG TGGCAGGGGA GGCCGAGGAG GAGGAAGAGG AGGAGGTGGC 840
AGAGGTGGTG GCAGAGGCGG TGGTTTTAGA GGTGGAAGAG GAGGTGGAGG TGGGGGCTTC 900 AGAGGAGGAA GAGGTGGTGG TTTCAGAGGG AGAGGACATT AAGTGAAACA GCTGACAGAC 960
ATCACCAGTT GACTTCTGCA TTAACCTGCA TGATCTGTTT CTACTATGGA TTGGAAACTT 1020
GTTTCTTGAA CAAGTCTTGA AGATC 1045
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 217 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met Ser Phe Arg Gly Gly Gly Arg Gly Gly Phe Asn Arg Gly Gly Gly 1 5 10 15
Gly Gly Gly Phe Asn Arg Gly Gly Ser Ser Asn His Phe Arg Gly Gly
20 25 30
Gly Gly Gly Gly Gly Gly Gly Asn Phe Arg Gly Gly Gly Arg Gly Gly 35 40 45
Phe Gly Arg Gly Gly Gly Arg Gly Gly Phe Asn Lys Gly Gin Asp Gin
50 55 60
Gly Pro Pro Glu Arg Val Val Leu Leu Gly Glu Phe Leu His Pro Cys 65 70 75 80 Glu Asp Asp lie Val Cys Lys Cys Thr Thr Asp Glu Asn Lys Val Pro
85 90 95
Tyr Phe Asn Ala Pro Val Tyr Leu Glu Asn Lys Glu Gin lie Gly Lys
100 105 110
Val Asp Glu lie Phe Gly Gin Leu Arg Asp Phe Tyr Phe Ser Val Lys 115 120 125
Leu Ser Glu Asn Met Lys Ala Ser Ser Phe Lys Lys Leu Gin Lys Phe
130 135 140
Tyr lie Asp Pro Tyr Lys Leu Leu Pro Leu Gin Arg Phe Leu Pro Arg 145 150 155 160 Pro Pro Gly Glu Lys Gly Pro Pro Arg Gly Gly Gly Arg Gly Gly Arg
165 170 175
Gly Gly Gly Arg Gly Gly Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly
180 185 190
Phe Arg Gly Gly Arg Gly Gly Gly Gly Gly Gly Phe Arg Gly Gly Arg 195 200 205
Gly Gly Gly Phe Arg Gly Arg Gly His 210 215
(2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1248 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
TTAAGGGGAA TAAAACACTT TATTTTAAAA ATTCAAATTA TCCTTCAAAT GAAAACTCCT 60 ATCCATTTAT TGAGCACCCA CAGAGTGCCA GGCACTGTAC AAAACATTAG AAAGACTTGT 120
TCATGCTCTT TTAGAGCNAA ATTCACTATT CCGTTGCACT TTGCATGATG CTGACATTTT 180
AGATCCATTG TCATAAAATG ACCAAGATCT TCAAGACTTG TTCAAGAAAC AAGTTTCCAA 240
TCCATAGTAG AAACAGATCA TGCAGGTTAA TGCAGAAGTC AACTGGTGAT GTCTGTCAAC 300
TGTTTCACTT AATGTCCTCT CCCTCTGAAA CCACCACCTC TTCCTCCTCT GAAGCCCCCA 360 CCTCCACCTC CTCTTCCACC TCTAAAACCA CCGCCTCTGC CACCACCTCT GCCACCTCCT 420
CCTCTTCCTC CTCCTCGGCC TCCCCTGCCA CCACCTCTTG GAGGTCCTTT CTCACCTGGA 480
GGTCGAGGTA AAAACCTCTG CAGTGGCAGC AGCTTATATG GGTCTATATA AAACTTCTGT 540
AGTTTTTTAA AGGATGAAGC CTTCATGTTT TCTGACAACT TAACTGAAAA ATAAAAATCT 600
CTGAGTTGTC CAAATATTTC CTCCACTTTT CCAATTTGTT CTTTGTTTTC TAAGTAAACA 660 GGAGCATTGA AATAAGGCAC CTTATTTTCA TCTGTGGTAC ATTTACAAAC TATGTCATCT 720
TCACAGGGAT GCAGGAACTC TCCTAATAAG ACTACACGTT CTGGAGGTCC TTGGTCTTGG 780
CCTTTGTTAA AGCCTCCGCG GCCACCCCCT CGTCCAAATC CTCCCCTGCC GCCGCCTCTG 840
AAATTGCCGC CGCCTCCACC GCCGCCTCCA CCTCGGAAGT GGTTGCTGCT GCCACCTCGG 900
TTGAAGCCGC CACCTCCACC ACCTCGATTA AAGCCTCCAC GACCTCCGCC TCGAAAAGAC 960 ATTCTCTCTC CTCCCGGCGC CACGTGCCCC TCTGGCCCTG GCCTTGCGCA CACACCCACC 1020
CGCGGGGTAC TTCCGCCGCG CTGGAACCTC CTCGGTTACC GTACCGCCAC AGAGTTTTTT 1080
AAAGACCAGA AACTTGAATA ACTGGTTTGC CAAAAAAAAA AAGCCAATCA CCCGCGGAAC 1140
AAGCAACACT GGTTCCAAAA CAGCCTTTAG CGCTGGAAAA GTGGCAATAA TAGATAACCT 1200
TAACCACTAA TTTACAACAG AGAGGCCAAC TTGCCTGACG NCTCTGCC 1248
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: :
Cys Thr Thr Asp Glu Asn Lys Val Pro Tyr Phe Asn Ala Pro Val Tyr
1 5 10 15
Leu Glu Asn Lys Glu Gin lie Gly Lys Val Glu Glu lie Phe Gly Gin 20 25 30
Leu Arg Asp Phe Tyr Phe Ser Val Lys Leu Ser Glu Asn Met Lys Ala
35 40 45
Ser Ser Phe Lys Lys Leu Gin Lys Phe Tyr lie Asp Pro Tyr Lys Leu 50 55 60 Leu Pro Leu Gin Arg Phe Leu Pro Arg Pro Pro Gly Glu Lys Gly Pro 65 70 75 80
Pro Arg Gly Gly Gly Arg Gly Gly Arg Gly Gly Gly Arg Gly Gly Gly
85 90 95
Gly Arg Gly Gly Gly Arg Gly Gly Gly Phe Arg Gly Gly Arg Gly Gly 100 105 110
Gly Gly Gly Gly Phe Arg Gly Gly Gly Gly Gly Arg Gly Gly Phe Asn
115 120 125
Arg Gly Gly Gly Gly Gly Gly Phe Asn Arg Gly Gly Ser Ser Asn His 130 135 140 Phe Arg Gly Gly Gly Gly Gly Gly Gly Gly Gly Asn Phe Arg Gly Gly 145 150 155 160
Gly Arg Gly Gly Phe Gly Arg Gly Gly Gly Arg Gly Gly Phe Asn Lys
165 170 175
Gly Gin Asp Gin Gly Pro Pro Glu Arg Val Val Leu Leu Gly Glu Phe
180 185 190
Leu His Pro Cys Glu Asp Asp lie Val Cys Lys 195 200
Claims
1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the HOQBQ59 polypeptide of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO:l encoding the HOQBQ59 polypeptide of SEQ ID NO2.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO: 1 over its entire length.
4. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
5. The polynucleotide of claim 1 which is DNA or RNA.
6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a HOQBQ59 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
7. A host cell comprising the expression system of claim 6.
8. A process for producing a HOQBQ59 polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
9. A process for producing a cell which produces a HOQBQ59 polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a HOQBQ59 polypeptide.
10. A HOQBQ59 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO: 2 over its entire length.
11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
12. An antibody immunospecific for the HOQBQ59 polypeptide of claim 10.
13. A method for the treatment of a subject in need of enhanced activity or expression of HOQBQ59 polypeptide of claim 10 comprising:
(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or
(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the HOQBQ59 polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence in a form so as to effect production of said polypeptide activity in vivo.
14. A method for the treatment of a subject having need to inhibit activity or expression of HOQBQ59 polypeptide of claim 10 comprising:
(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; and/or
(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate , or receptor.
15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of HOQBQ59 polypeptide of claim 10 in a subject comprising: (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said HOQBQ59 polypeptide in the genome of said subject; and/or
(b) analyzing for the presence or amount of the HOQBQ59 polypeptide expression in a sample derived from said subject.
16. A method for identifying compounds which inhibit (antagonize) or agonize the HOQBQ59 polypeptide of claim 10 which comprises:
(a) contacting a candidate compound with cells which express the HOQBQ59 polypeptide (or cell membrane expressing HOQBQ59 polypeptide) or respond to HOQBQ59 polypeptide; and
(b) observing the binding, or stimulation or inhibition of a functional response; or comparing the abihty of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for HOQBQ59 polypeptide activity.
17. An agonist identified by the method of claim 16.
18. An antagonist identified by the method of claim 16.
19. A recombinant host cell produced by a method of Claim 9 or a membrane thereof expressing a HOQBQ59 polypeptide.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5200997P | 1997-07-09 | 1997-07-09 | |
US60/052,009 | 1997-07-09 | ||
US96923997A | 1997-11-13 | 1997-11-13 | |
US08/969,239 | 1997-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999002560A1 true WO1999002560A1 (en) | 1999-01-21 |
Family
ID=26730056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/014291 WO1999002560A1 (en) | 1997-07-09 | 1998-07-09 | Hoqbq59 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1999002560A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0892050A2 (en) * | 1997-07-08 | 1999-01-20 | Smithkline Beecham Corporation | Human HFIZG53 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604113A (en) * | 1994-04-07 | 1997-02-18 | Rutgers University | Cells having oncogene-suppressed p53-mediated apoptosis and methods of use to identify anti-oncogenic compounds |
-
1998
- 1998-07-09 WO PCT/US1998/014291 patent/WO1999002560A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604113A (en) * | 1994-04-07 | 1997-02-18 | Rutgers University | Cells having oncogene-suppressed p53-mediated apoptosis and methods of use to identify anti-oncogenic compounds |
Non-Patent Citations (2)
Title |
---|
CALDWELL J: "THE IMPORTANCE OF DRUG METABOLISM STUDIES FOR EFFICIENT DRUG DISCOVERY AND DEVELOPMENT", YAKUBUTSU DOTAI - XENOBIOTIC METABOLISM AND DISPOSITION, NIHON YAKUBUTSU DOTAI GAKKAI, TOKYO,, JP, vol. 11, no. 01, 1 January 1996 (1996-01-01), JP, pages 119 - 126, XP002911641, ISSN: 0916-1139 * |
NGO J T, MARKS J, KARPLUS M: "COMPUTATIONAL COMPLEXITY, PROTEIN STRUCTURE PREDICTION, AND THE LEVINTHAL PARADOX", PROTEIN FOLDING PROBLEM AND TERTIARY STRUCTURE PREDICTION, XX, XX, 1 January 1994 (1994-01-01), XX, pages 433 + 492 - 495, XP002911640 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0892050A2 (en) * | 1997-07-08 | 1999-01-20 | Smithkline Beecham Corporation | Human HFIZG53 |
EP0892050A3 (en) * | 1997-07-08 | 2002-04-17 | Smithkline Beecham Corporation | Human HFIZG53 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6319688B1 (en) | Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1) | |
WO1999021991A1 (en) | Bmzf12: a zinc finger gene cloned from bone marrow | |
EP0848062A2 (en) | Aspartic protease ASP1 | |
EP0887414A2 (en) | Human serine proteases HGBAB90 | |
EP0854191A2 (en) | Human cardiac/brain tolloid-like protein | |
WO1999035266A2 (en) | Human urotensin ii | |
EP0894855A2 (en) | Human I kappa B-beta transcription factor | |
US5837508A (en) | Membrane-type matrix metalloproteinase-5 gene | |
WO2000026374A2 (en) | Adipose specific protein | |
CA2230996A1 (en) | Novel compounds | |
US5932446A (en) | Hmvab41 | |
WO1999002560A1 (en) | Hoqbq59 | |
WO1999021988A1 (en) | THE HUMAN VESICLE TRAFFICKING PROTEIN SEC22b GENE OF CBFBBA01 | |
EP0889126A2 (en) | YNL075W/HTXFT19 polypeptide | |
EP0892050A2 (en) | Human HFIZG53 | |
EP0887406A2 (en) | A member of the FRZB family, franzzled | |
WO1999022006A1 (en) | CBLAFC02: A SUBUNIT OF VACUOLAR H(+)-ATPase | |
WO1999021885A1 (en) | A human abc transporter-7 (habc7) gene | |
EP0879886A2 (en) | Signal transduction protein HLDAT86, the human Wnt-4 homolog | |
EP0892049A2 (en) | A human pelota homolog | |
WO1999046290A1 (en) | A human angiotensin ii/vasopressin receptor (aii/avp) like gene (cbdakd01) | |
EP0897979A2 (en) | Human sdr2 cdna clone | |
WO1999021986A1 (en) | Cbfbga09: a human sl15 homolog | |
WO1999021982A1 (en) | Human m6b1 gene | |
WO1999036527A1 (en) | An ataxin-2 like gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1999508944 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |